This October 29th, the Janssen Pharmaceutical Companies of Johnson & Johnson join the International Federation of Psoriasis Associations in support of World Psoriasis Day, an annual event dedicated to raising awareness of an autoimmune disease that affects 125 million people worldwide.
At Janssen, our commitment to people living with psoriatic disease has never been stronger, both through the medicines that we offer today and through our continued research and development to advance the next generation of therapies for the future.
We are motivated to go further by the personal impact of psoriasis and psoriatic arthritis, pursuing approaches that will hopefully one day intercept and even prevent psoriatic disease altogether.
Every day, these efforts bring us closer to realizing our vision of #aworldfreefrom immune and inflammatory diseases, an aspirational goal but one that we believe is achievable for people living with or who may develop psoriatic disease in the future.
Anne Fourie, PhD, is Disease Area Leader, Psoriasis, Janssen Research & Development, LLC
Irene Hsu, PharmD, MBA, is Vice President, Commercial Disease Area Leader, Rheumatoid Arthritis and Psoriasis, Janssen Pharmaceutical Companies of Johnson & Johnson.